Clinical Laserthermia Systems AB (publ)

OM:CLS UR B Stock Report

Market Cap: SEK 22.3m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Clinical Laserthermia Systems Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Dan Mogren

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure2.6yrs
CEO ownershipn/a
Management average tenureless than a year
Board average tenure3yrs

Recent management updates

No updates

Recent updates

No updates

CEO Compensation Analysis

How has Dan Mogren's remuneration changed compared to Clinical Laserthermia Systems's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2023n/an/a

-SEK 78m

Dec 31 2022n/an/a

-SEK 71m

Sep 30 2022n/an/a

-SEK 81m

Jun 30 2022n/an/a

-SEK 63m

Mar 31 2022n/an/a

-SEK 68m

Dec 31 2021SEK 2mSEK 1m

-SEK 64m

Compensation vs Market: Insufficient data to establish whether Dan's total compensation is reasonable compared to companies of similar size in the Swedish market.

Compensation vs Earnings: Insufficient data to compare Dan's compensation with company performance.

CEO

Dan Mogren

2.6yrs

Tenure

SEK 1,551,882

Compensation

Mr. Dan J. Mogren was Acting Chief Executive Officer at Clinical Laserthermia Systems AB (publ) since December 01, 2020 until May 2022 and is Chief Executive Officer May 2022 and served as its Chief Commer...

Leadership Team

NamePositionTenureCompensationOwnership
Dan Mogren
Chief Executive Officer2.6yrsSEK 1.55mno data
Lars-Erik Eriksson
Co-Founder & Directorno dataSEK 1.65mno data
Rolf Bornschein
Chief Financial Officerless than a yearno datano data
Jimmy Johansson
Executive Vice President of Operationsless than a yearno datano data
Stephan Dymling
Head of Technical Developmentno datano datano data
Karin Peterson
Chief Product Officerno datano datano data
Mats Ekelund
Chief Medical Officerno datano datano data

0.8yrs

Average Tenure

Experienced Management: CLS UR B's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Lars-Erik Eriksson
Co-Founder & Director17.5yrsSEK 1.65mno data
Hans von Celsing
Independent Chairman of the Board10.5yrsSEK 285.00k0.22%
SEK 48.9k
Gunilla Savring
Independent Director3.5yrsSEK 142.50kno data
Rolf Kiessling
Member of Clinical Advisory Board2.1yrsSEK 80.00kno data
Karl-Göran Tranberg
Member of Clinical Advisory Board2.1yrsSEK 80.00k0.90%
SEK 200.9k
Paolo Raffaelli
Independent Director2.5yrsSEK 62.50kno data
Marika Crohns
Independent Director & Member of Clinical Advisory Board3.5yrsSEK 142.50kno data
Sandy Brandmeier
Independent Director2.5yrsno datano data

3.0yrs

Average Tenure

67.5yo

Average Age

Experienced Board: CLS UR B's board of directors are considered experienced (3 years average tenure).